Background: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell
lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta …

Background: The meta-analysis aimed to compare the efficacy and safety of erlotinib versus
(vs.) chemotherapy (docetaxel/pemetrexed) as second-line therapy in advanced non-small …

Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …

Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …

Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …

We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Introduction: Erlotinib was recently approved in British Columbia (BC) as a second-line
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …

Introduction. The aim of this retrospective study was to examine effect of erlotinib in patients
with advanced non‐small cell lung cancer (NSCLC) in second‐line and further therapy in …